4.6 Review

From regenerative strategies to pharmacological approaches: can we fine-tune treatment for Parkinson's disease?

Journal

NEURAL REGENERATION RESEARCH
Volume 17, Issue 5, Pages 933-936

Publisher

WOLTERS KLUWER MEDKNOW PUBLICATIONS
DOI: 10.4103/1673-5374.324827

Keywords

disease-modifying strategies; mesenchymal stem cells; N-acetylcysteine; neuroprotection; Parkinson's disease; stem cells secretome

Funding

  1. Premios Santa Casa Neurociencias Prize Mantero Belard for Neurodegenerative Diseases Research [MB-28-2019]
  2. European Regional Development Fund (FEDER), through the Competitiveness Internationalization Operational Programme (POCI)
  3. Foundation for Science and Technology (FCT) [UIDB/50026/2020, UIDP/50026/2020, POCI-01-0145-FEDER-029751]
  4. Northern Portugal Regional Operational Programme (NORTE 2020), under the Portugal 2020 Partnership Agreement, through the European Regional Development Fund (FEDER) [NORTE01-0145-FEDER-000023]
  5. ICVS Scientific Microscopy Platform [PPBI-POCI-01-0145-FEDER-022122]

Ask authors/readers for more resources

Parkinson's disease is a common neurodegenerative disease, and the current treatment focuses on symptom relief rather than prevention of neuronal damage. Therefore, the development of neuroprotective and disease-modifying strategies is crucial. Stem cell secretome has shown promise as a potential alternative for regenerative medicine in Parkinson's disease, as it can modulate the viability and preservation of dopaminergic neurons.
Parkinson's disease is the second most prevalent neurodegenerative disorder worldwide. Clinically, it is characterized by severe motor complications caused by progressive degeneration of dopaminergic neurons. Current treatment is focused on mitigating the symptoms through the administration of levodopa, rather than on preventing dopaminergic neuronal damage. Therefore, the use and development of neuroprotective/disease-modifying strategies is an absolute need that can lead to promising gains on translational research of Parkinson's disease. For instance, N-acetylcysteine, a natural compound with strong antioxidant effects, has been shown to modulate oxidative stress, preventing dopamine-induced cell death. Despite the evidence of neuroprotective and modulatory effects of this drug, as far as we know, it does not induce per se any regenerative process. Therefore, it would be of interest to combine the latter with innovative therapies that induce dopaminergic neurons repair or even differentiation, as stem cell-based strategies. Stem cells secretome has been proposed as a promising therapeutic approach for Parkinson's disease, given its ability to modulate cell viability/preservation of dopaminergic neurons. Such approach represents a shift in the paradigm, showing that cell-transplantation free therapies based on the use of stem cells secretome may represent a potential alternative for regenerative medicine of Parkinson's disease. Thus, in this review, we address the current understanding of the potential combination of stem cell free-based strategies and neuroprotective/disease-modifying strategies as a new paradigm for the treatment of central nervous system neurodegenerative diseases, like Parkinson's disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available